Immunotherapy Drugs Market by Type of Drugs (Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha), Therapy Area (Cancer, Autoimmune Diseases, Infectious Diseases), End-User (Hospitals), Region (North America, Asia-Pacific) - Global Forecast to 2021

免疫療法治療薬の世界市場予測(~2021):薬種類別(成人用ワクチン、チェックポイント阻害剤、インターフェロンアルファ)、治療分野別、需要先別、地域別

◆タイトル:Immunotherapy Drugs Market by Type of Drugs (Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha), Therapy Area (Cancer, Autoimmune Diseases, Infectious Diseases), End-User (Hospitals), Region (North America, Asia-Pacific) - Global Forecast to 2021
◆商品コード:MAM-PH-3926
◆調査・発行会社:MarketsandMarkets
◆発行日:2017年1月6日
◆ページ数:176
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD5,650 ⇒換算¥621,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥731,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥896,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、免疫療法治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、産業動向、市場シェア分析、薬種類別分析、治療分野別分析、需要先別分析、地域別分析、免疫療法治療薬の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

The global immunotherapy drugs market is projected to reach USD 201.52 Billion by 2021 from USD 108.41 Billion in 2016, growing at a CAGR of 13.5% during the forecast period of 2016 to 2021.
Increasing adoption of targeted therapies with fewer side effects, quicker drug approval processes, and high prevalence rate of lifestyle diseases are major growth drivers of this market. On the other hand, the high cost of immunotherapy treatment, and high attrition rate in the product development cycle are the major factors hindering the growth of the market. However, rising opportunities in the emerging markets, and immunotherapy as an alternative to chemotherapy for first line treatment are the factors supporting the growth of the market.

The immunotherapy drugs market is segmented on the basis of type of drugs, therapy area, end user, and region. Based on type of drugs, the market is segmented into monoclonal antibodies, adult vaccines, checkpoint inhibitors, interferons alpha & beta, interleukins, and others. Adult vaccines segment is further categorized into preventive vaccines and therapeutic vaccines. Monoclonal antibodies segment is expected to account for the largest market share in the market, by type of drugs in 2016. On the other hand, checkpoint inhibitors segment is expected to be the fastest growing segment in the market, by type of drugs, in 2016. The high growth of this segment can be attributed to factors such as increasing adoption of checkpoint inhibitors in cancer treatment with their ability to target only foreign cells leaving normal cells alone.

On the basis of therapy area, the immunotherapy drugs market is segmented into cancer, autoimmune & inflammatory diseases, infectious diseases, and others. Among these segments, the cancer segment is expected to account for the largest market share in 2016. Cancer segment is also expected to be the fastest growing segment in the market, by therapy area in 2016. The large share and high growth of this segment can be attributed to factor such as high preference for immunotherapy as a first line of treatment in cancer leading to growing demand for immunotherapy drugs.

North America is expected to account for largest share in the immunotherapy drugs market, by region in 2016. Asia-Pacific is expected to be the fastest-growing regional segment in the market. The high growth of this segment can primarily be attributed to the low cost of manufacturing and acceptable regulatory scenario in this region.

The major players operating in the immunotherapy drugs market include F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline (U.K.), AbbVie, Inc. (U.S.), Amgen, Inc. (U.S.), Merck & Co., Inc. (U.S.). Bristol-Myers Squibb (U.S.), Novartis International AG (Switzerland), Eli Lilly and Company (U.S.), Johnson & Johnson (U.S.), and AstraZeneca plc (U.K.).

【レポートの目次】

1 Introduction (Page No. – 15)
1.1 Objectives of the Study
1.2 Market Definition
1.2.1 Markets Covered
1.2.2 Years Considered for the Study
1.3 Currency ‘
1.4 Limitations
1.5 Stakeholders

2 Research Methodology (Page No. – 18)
2.1 Market Size Estimation
2.2 Market Breakdown and Data Triangulation
2.3 Market Share Estimation
2.3.1 Key Data From Secondary Sources
2.3.2 Key Data From Primary Sources
2.3.3 Assumptions for the Study

3 Executive Summary (Page No. – 25)
3.1 Introduction
3.2 Conclusion

4 Premium Insights (Page No. – 30)
4.1 Global Immunotherapy Drugs Market Overview
4.2 Market: By Therapy Area & Region
4.3 Market: Geographic Snapshot
4.4 Market, By Type of Drug
4.5 Life Cycle Analysis, By Region (2016)

5 Market Overview (Page No. – 33)
5.1 Introduction
5.1.1 Drivers
5.1.1.1 Increasing Adoption of Targeted Therapy Over Traditional Therapy
5.1.1.2 Emergence of Biosimilars
5.1.1.3 Increasing Demand for Mabs
5.1.1.4 High Prevalence Rate of Lifestyle Diseases
5.1.1.5 Fast Track and Orphan Drug Designations
5.1.2 Restraints
5.1.2.1 High Cost of Immunotherapy Treatment
5.1.2.2 High Attrition Rate in the Product Development Cycle
5.1.3 Opportunities
5.1.3.1 Emerging Markets
5.1.3.2 Immunotherapy to Replace Chemotherapy in Cancer Treatment
5.1.4 Challenge
5.1.4.1 Impending Patent Expiry of Top-Selling Biologics

6 Industry Insights (Page No. – 39)
6.1 Introduction
6.2 Epidemiology Coverage
6.2.1 Cancer Epidemiology
6.2.2 Autoimmune Disease Epidemiology
6.3 Pricing and Reimbursement Scenario
6.3.1 U.S.
6.3.2 U.K.
6.3.3 France
6.3.4 Germany
6.3.5 Other European Countries
6.3.6 Japan
6.4 Research Funding & Government Initiatives
6.5 Pipeline Drugs
6.5.1 Phase 1
6.5.2 Phase I/II
6.5.3 Phase II
6.5.4 Phase II/III
6.5.5 Phase III
6.5.6 Application Submitted
6.5.7 Promising Molecules
6.6 Industry Trends
6.7 Key Products Expected to Be Launched
6.8 Treatment Protocols and Line of Therapies
6.8.1 First-Line Therapy
6.8.2 Second-Line Therapy
6.8.3 Other Treatments
6.9 Burning Issues

7 Immunotherapy Drugs Market, By Type of Drug (Page No. – 67)
7.1 Introduction
7.2 Monoclonal Antibodies
7.3 Adult Vaccines
7.3.1 Preventive Vaccines
7.3.2 Therapeutic Vaccines
7.4 Checkpoint Inhibitors
7.5 Interferons Alpha & Beta
7.6 Interleukins
7.7 Other Drugs

8 Immunotherapy Drugs Market, By Therapy Area (Page No. – 79)
8.1 Introduction
8.2 Cancer
8.3 Autoimmune and Inflammatory Diseases
8.4 Infectious Diseases
8.5 Other Therapy Areas

9 Immunotherapy Drugs Market, By End User (Page No. – 88)
9.1 Introduction
9.2 Hospitals
9.3 Clinics
9.4 Other End Users

10 Immunotherapy Drugs Market, By Region (Page No. – 93)
10.1 Introduction
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 U.K.
10.3.3 France
10.3.4 Italy
10.3.5 Spain
10.4 Asia-Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.5 Rest of the World (RoW)

11 Competitive Landscape (Page No. – 116)
11.1 Introduction
11.2 Strategic Analysis
11.3 Market Share Analysis
11.4 Competitive Situation and Trends
11.4.1 Regulatory Approvals
11.4.2 Collaborations
11.4.3 Agreements
11.4.4 Acquisitions
11.4.5 Expansions

12 Company Profiles (Page No. – 124)
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
12.1 Introduction
12.2 F. Hoffmann-La Roche AG
12.3 Merck & Co., Inc.
12.4 Novartis International AG
12.5 Johnson & Johnson (A Parent Company of Janssen Biotech, Inc.)
12.6 Glaxosmithkline PLC
12.7 Amgen Inc.
12.8 Abbvie
12.9 Astrazeneca
12.10 Bristol-Myers Squibb
12.11 ELI Lilly and Company

*Details on Marketsandmarkets View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.

13 Appendix (Page No. – 157)
13.1 Insights of Industry Experts
13.2 Discussion Guide
13.3 Other Developments
13.4 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.5 Introducing RT: Real-Time Market Intelligence
13.6 Available Customizations
13.7 Related Reports
13.8 Author Details

List of Tables (79 Tables)

Table 1 Immunotherapy Drugs Market Summary
Table 2 Comparison of Cost (Branded vs Biosimilar Version)
Table 3 Cancer: Estimated Incidence, Mortality in Men (2015)
Table 4 Cancer: Estimated Incidence, Mortality in Women (2015)
Table 5 Global Market Size, By Type of Drug, 2014–2021 (USD Billion)
Table 6 Global Monoclonal Antibodies Market Size, By Region, 2014–2021 (USD Billion)
Table 7 North America: Monoclonal Antibody Market Size, By Country, 2014–2021 (USD Billion)
Table 8 Global Adult Vaccines Market Size, By Type, 2014–2021 (USD Billion)
Table 9 Global Adult Vaccines Market Size, By Region, 2014–2021 (USD Billion)
Table 10 North America: Adult Vaccines Market Size, By Country, 2014–2021 (USD Billion)
Table 11 Global Preventive Vaccines Market Size, By Region, 2014–2021 (USD Billion)
Table 12 North America: Preventive Vaccines Market Size, By Country, 2014–2021 (USD Billion)
Table 13 Global Therapeutic Vaccines Market Size, By Region, 2014–2021 (USD Billion)
Table 14 North America: Therapeutic Vaccines Market Size, By Country, 2014–2021 (USD Billion)
Table 15 Global Checkpoint Inhibitors Market Size, By Region, 2014–2021 (USD Billion)
Table 16 North America: Checkpoint Inhibitors Market Size, By Country, 2014–2021 (USD Billion)
Table 17 Global Interferons Alpha & Beta Market Size, By Region, 2014–2021 (USD Billion)
Table 18 North America: Interferons Alpha & Beta Market Size, By Country, 2014–2021 (USD Billion)
Table 19 Global Other Drugs Market Size, By Region, 2014–2021 (USD Billion)
Table 20 North America: Other Drugs Market Size, By Country, 2014–2021 (USD Billion)
Table 21 Global Market Size, By Therapy Area, 2014–2021 (USD Billion)
Table 22 Global Market Size for Cancer, By Type, 2014–2021 (USD Billion)
Table 23 GlobalMarket Size for Cancer, By Region, 2014–2021 (USD Billion)
Table 24 North America: Global Market Size for Cancer, By Country, 2014–2021 (USD Billion)
Table 25 Global Cancer Market Size for Solid Tumors, By Region, 2014–2021 (USD Billion)
Table 26 North America: Global Cancer Market Size for Solid Tumors, By Country, 2014–2021 (USD Billion)
Table 27 Global Cancer Market Size for Malignant Tumors, By Region, 2014–2021 (USD Billion)
Table 28 North America: Global Cancer Market Size for Malignant Tumors, By Country, 2014–2021 (USD Billion)
Table 29 Global Market Size for Autoimmune and Inflammatory Diseases, By Region, 2014–2021 (USD Billion)
Table 30 North America: Global Market Size for Autoimmune and Inflammatory Diseases, By Country, 2014–2021 (USD Billion)
Table 31 Global Market Size for Infectious Diseases, By Region, 2014–2021 (USD Billion)
Table 32 North America: Global Market Size for Infectious Diseases, By Country, 2014–2021 (USD Billion)
Table 33 Global Market Size for Other Therapy Areas, By Region, 2014–2021 (USD Billion)
Table 34 North America: Global Market Size for Other Therapy Areas, By Country, 2014–2021 (USD Billion)
Table 35 Global Market Size, By End User, 2014–2021 (USD Billion)
Table 36 Global Market Size for Hospitals, By Region, 2014–2021 (USD Billion)
Table 37 North America: Global Market Size for Hospitals, By Country, 2014–2021 (USD Billion)
Table 38 Global Immunotherapy Drugs Market Size for Clinics, By Region, 2014–2021 (USD Billion)
Table 39 North America: Global Immunotherapy Drugs Market Size for Clinics, By Country, 2014–2021 (USD Billion)
Table 40 Global Immunotherapy Drugs Market Size for Other End Users, By Region, 2014–2021 (USD Billion)
Table 41 North America: Global Immunotherapy Drugs Market Size for Other End Users, By Country, 2014–2021 (USD Billion)
Table 42 Global Immunotherapy Drugs Market Size, By Region, 2014–2021 (USD Billion)
Table 43 North America: Immunotherapy Drugs Market Size, By Country, 2014–2021 (USD Billion)
Table 44 North America: Immunotherapy Drugs Market Size, By Type of Drug, 2014–2021 (USD Billion)
Table 45 North America: Adult Vaccines Market Size, By Type, 2014–2021 (USD Billion)
Table 46 North America: Immunotherapy Drugs Market Size, By Therapy Area, 2014–2021 (USD Billion)
Table 47 North America: Immunotherapy Drugs Market Size for Cancer, By Type, 2014–2021 (USD Billion)
Table 48 North America: Immunotherapy Drugs Market Size, By End User, 2014–2021 (USD Billion)
Table 49 U.S.: Immunotherapy Drugs Market Size, By Type of Drug, 2014–2021 (USD Billion)
Table 50 U.S.: Adult Vaccines Market Size, By Type, 2014–2021 (USD Billion)
Table 51 The U.S.: Immunotherapy Drugs Market Size, By Therapy Area, 2014–2021 (USD Billion)
Table 52 U.S.: Immunotherapy Drugs Market Size for Cancer, By Type, 2014–2021 (USD Billion)
Table 53 The U.S.: Immunotherapy Drugs Market Size, By End User, 2014–2021 (USD Billion)
Table 54 Canada: Immunotherapy Drugs Market Size, By Type of Drug, 2014–2021 (USD Billion)
Table 55 Canada: Adult Vaccines Market Size, By Type, 2014–2021 (USD Billion)
Table 56 Canada: Immunotherapy Drugs Market Size, By Therapy Area, 2014–2021 (USD Billion)
Table 57 Canada: Immunotherapy Drugs Market Size for Cancer, By Type, 2014–2021 (USD Billion)
Table 58 Canada: Immunotherapy Drugs Market Size, By End User, 2014–2021 (USD Billion)
Table 59 Europe: Immunotherapy Drugs Market Size, By Type of Drug, 2014–2021 (USD Billion)
Table 60 Europe: Adult Vaccines Market Size, By Type, 2014–2021 (USD Billion)
Table 61 Europe: Immunotherapy Drugs Market Size, By Therapy Area, 2014–2021 (USD Billion)
Table 62 Europe: Immunotherapy Drugs Market Size for Cancer, By Type, 2014–2021 (USD Billion)
Table 63 Europe: Immunotherapy Drugs Market Size, By End User, 2014–2021 (USD Billion)
Table 64 APAC.: Immunotherapy Drugs Market Size, By Type of Drug, 2014–2021 (USD Billion)
Table 65 APAC: Adult Vaccines Market Size, By Type, 2014–2021 (USD Billion)
Table 66 APAC: Immunotherapy Drugs Market Size, By Therapy Area, 2014–2021 (USD Billion)
Table 67 APAC: Immunotherapy Drugs Market Size for Cancer, By Type, 2014–2021 (USD Billion)
Table 68 APAC: Immunotherapy Drugs Market Size, By End User, 2014–2021 (USD Billion)
Table 69 RoW: Immunotherapy Drugs Market Size, By Type of Drug, 2014–2021 (USD Billion)
Table 70 RoW: Adult Vaccines Market Size, By Type, 2014–2021 (USD Billion)
Table 71 RoW: Immunotherapy Drugs Market Size, By Therapy Area, 2014–2021 (USD Billion)
Table 72 RoW: Immunotherapy Drugs Market Size for Cancer, By Type, 2014–2021 (USD Billion)
Table 73 RoW: Immunotherapy Drugs Market Size, By End User, 2014–2021 (USD Billion)
Table 74 Market Developments, 2013–2016
Table 75 Approvals, 2013–2016
Table 76 Collaborations, 2013–2016
Table 77 Agreements, 2013–2016
Table 78 Acquisitions, 2013–2016
Table 79 Expansions, 2013–2016


List of Figures (44 Figures)

Figure 1 Research Design
Figure 2 Market Size Estimation Methodology: Bottom-Up Approach
Figure 3 Market Size Estimation Methodology: Top-Down Approach
Figure 4 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 5 Data Triangulation Methodology
Figure 6 Immunotherapy Drugs Market Size, By Type of Drug, 2016 vs 2021 (USD Billion)
Figure 7 Immunotherapy Drugs Market Size, By Therapy Area, 2016 vs 2021 (USD Billion)
Figure 8 Immunotherapy Drugs Market Size, By End User, 2016 vs 2021 (USD Billion)
Figure 9 Immunotherapy Drugs Market, By Region, 2016
Figure 10 Immunotherapy Drugs Market Size, By Region, 2016 vs 2021 (USD Billion)
Figure 11 Increasing Adoption of Target Therapy Over Traditional Therapy to Drive Market Growth
Figure 12 Cancer to Command the Largest Market Share in 2016
Figure 13 Asia to Register Highest Growth During the Forecast Period
Figure 14 Checkpoint Inhibitors Expected to Be the Fastest-Growing Segment
Figure 15 Asia Presents Lucrative Growth Opportunities in the Immunotherapy Drugs Market
Figure 16 Increasing Adoption of Targeted Therapy Over Traditional Therapy Will Drive the Immunotherapy Drugs Market
Figure 17 Rise in Costs of Cancer Immunotherapy Drugs
Figure 18 Percentage of Adult Population Diagnosed With Autoimmune Diseases (October 2016)
Figure 19 Cancer Research Funding in 2014
Figure 20 Clinical Phases of Products to Be Launched
Figure 21 Monoclonal Antibodies Segment to Account for the Largest Market Share in 2016
Figure 22 Preventive Vaccines to Account for the Largest Share in 2016
Figure 23 Global Interleukins Market Size, 2016–2021 (USD Billion)
Figure 24 Cancer Account for the Largest Market Share in 2016
Figure 25 Hospitals to Dominate the Immunotherapy Drugs Market, By End User, During 2016–2021
Figure 26 Geographic Snapshot: Asia-Pacific, the Fastest-Growing Region in 2016–2021
Figure 27 Checkpoint Inhibitors Segment to Witness High Growth in the North American and Asia-Pacific Markets
Figure 28 North America: Immunotherapy Drugs Market Snapshot
Figure 29 U.S. to Dominate the North American Immunotherapy Drugs Market
Figure 30 Europe: Immunotherapy Drugs Market Snapshot
Figure 31 APAC: Immunotherapy Drugs Market Snapshot
Figure 32 Key Developments in the Immunotherapy Drugs Market, 2013–2016
Figure 33 Immunotherapy Drugs Market Share Analysis, By Key Player, 2015
Figure 34 Geographic Revenue Mix of the Top Five Market Players
Figure 35 F. Hoffmann-La Roche AG: Company Snapshot
Figure 36 Merck & Co., Inc.: Company Snapshot
Figure 37 Novartis International AG: Company Snapshot
Figure 38 Johnson & Johnson: Company Snapshot
Figure 39 Glaxosmithkline PLC: Company Snapshot
Figure 40 Amgen Inc.: Company Snapshot
Figure 41 Abbvie: Company Snapshot
Figure 42 Astrazeneca: Company Snapshot
Figure 43 Bristol-Myers Squibb: Company Snapshot
Figure 44 ELI Lilly and Company: Company Snapshot

【レポートのキーワード】

免疫療法治療薬、免疫療法治療薬種類、成人用ワクチン、チェックポイント阻害剤、インターフェロンアルファ、治療分野、免疫療法治療薬需要先、地域

★調査レポート[免疫療法治療薬の世界市場予測(~2021):薬種類別(成人用ワクチン、チェックポイント阻害剤、インターフェロンアルファ)、治療分野別、需要先別、地域別] ( Immunotherapy Drugs Market by Type of Drugs (Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha), Therapy Area (Cancer, Autoimmune Diseases, Infectious Diseases), End-User (Hospitals), Region (North America, Asia-Pacific) - Global Forecast to 2021 / MAM-PH-3926) 販売に関する免責事項
[免疫療法治療薬の世界市場予測(~2021):薬種類別(成人用ワクチン、チェックポイント阻害剤、インターフェロンアルファ)、治療分野別、需要先別、地域別] ( Immunotherapy Drugs Market by Type of Drugs (Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha), Therapy Area (Cancer, Autoimmune Diseases, Infectious Diseases), End-User (Hospitals), Region (North America, Asia-Pacific) - Global Forecast to 2021 / MAM-PH-3926) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆